Lianyue Ma

Dr. Lianyue Ma

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 July 2025 in Pharmacological Research
Verified
Journal Article
Open access
LMLianyue Ma
Lianyue Ma
WYWei Yang
Wei Yang
WGWei Gao
Wei Gao
XLXiangjuan Liu
Xiangjuan Liu
MDMei Dong
Mei Dong
XMXiao Meng
Xiao Meng
Interleukin-17 (IL-17), a pleiotropic cytokine produced by Th17 cells and innate immune cells, plays a pivotal role in cardiovascular diseases (CVDs) by bridging innate and adaptive immunity. Preclinical studies highlight its pro-inflammatory effects in atherosclerosis, myocardial infarction, hypertension, myocarditis, and heart failure, driving endothelial dysfunction, immune cell infiltration, oxidative stress, and tissue remodeling. Elevated IL-17 levels correlate with vulnerable plaque burden, adverse cardiac events, hypertension severity, and arrhythmogenesis. Paradoxically, IL-17 may stabilize plaques in specific contexts, underscoring its dual roles. Clinical data link IL-17 isoforms (e.g., IL-17A, IL-17E) to coronary artery disease progression and psychological comorbidities. While IL-17-targeted therapies (e.g., monoclonal antibodies) show promise in preclinical models, clinical outcomes remain heterogeneous, with controversies regarding cardiac adverse events (e.g.,coronary artery disease, pericarditis and atrial fibrillation) in autoimmune populations. Mechanistic insights emphasize IL-17's interactions with lipid metabolism, thrombotic pathways, and immune cross-talk. However, conflicting evidence on its protective versus detrimental effects necessitates further translational research. This review underscores the need for rigorous clinical trials to validate IL-17 modulation strategies in CVDs, balancing therapeutic benefits against potential adverse effects.

12 August 2025 in Scientific Reports
Verified
Journal Article
Open access
BWBaiqiang Wang
Baiqiang Wang
ZMZeyuan Mei
Zeyuan Mei
HYHong Yang
Hong Yang
WGWei Gao
Wei Gao
LMLianyue Ma
Lianyue Ma
GAGuipeng An
Guipeng An
The online version contains supplementary material available at 10.1038/s41598-025-14522-x.

13 April 2024 in ESC Heart Failure
Verified
Journal Article
Open access
HSHui Sun
Hui Sun
BWBaiqiang Wang
Baiqiang Wang
GAGuipeng An
Guipeng An
YZYun Zhang
Yun Zhang
LMLianyue Ma
Lianyue Ma
Aims: The predictive value of the lactate/albumin ratio (LAR) in mortality is established in various conditions, yet its relevance to 3-month readmission risk in Chinese adults with heart failure (HF) remains unclear. Method and results: Analysing data from 957 patients with HF at Zigong Fourth People's Hospital, Sichuan, China (December 2016 to June 2019), we assessed baseline characteristics, vital signs, comorbidities, and prescriptions. LAR demonstrated a linear correlation with 3-month readmission risk (HR = 1.60, 95% CI: 1.19–2.16). Tertile 3 (≥−0.48) exhibited higher risk than tertile 1 (<−0.83) and tertile 2 [−0.83, −0.48), with HRs and 95% CI of 1.49 (1.06–2.10), 1.43 (1.01–2.02), 1.48 (1.03–2.12), respectively. Subgroup and sensitivity analyses affirmed consistent influence of LAR on 3-month readmission risk for HF. Conclusions: Higher LAR significantly correlates with increased 3-month readmission risk in Chinese adult patients with HF, suggesting LAR is a valuable predictor for early readmission.